Lessons from a positive randomized trial of high-dose chemotherapy in metastatic breast cancer: learn from our mistakes, build on our successes, drain the bathwater, hold the baby  by Crown, J.P. et al.
had received 3 or more treatment regimens. Prior therapy included
R in half of all patients. 12 patients had never achieved a complete
remission, and 8 had primary refractory disease. Toxicity was
similar to that reported with BEAM alone and included a fall in
DLCO for most patients with 1 patient experiencing a transient
decline to below 50% of the predicted values corrected for hemo-
globin. Grade III/IV toxicities included infection, fever, stomatitis,
nausea, vomiting, diarrhea, hemorrhage, and edema. One patient
at the 700 cGy level developed veno-occlusive disease which con-
stituted a dose-limiting toxicity (maximum total bilirubin 10.4),
necessitating the enrollment of 3 additional patients at that dose
level. Ascites resolved by D 34, and total bilirubin was normal by
D 60. At the 700 cGy level, administered radioactivities ranged
from 0.27 to 0.73 mCi/kg (median: 0.37), and the total body dose
from 43 to 12 cGy (median: 99 cGy). In all but one case, the critical
organ was the liver. Engraftment by ABMTR criteria occurred at
a median of 10 days (range: 8-18) for 1000 granulocytes and 21
days (range: 12-40) for platelet recovery to 20,000. With a median
follow-up of 12 months, the OS is 60% at 3 years. PFS is 47% at
both 2 and 3 years. Accrual continues at the 900 cGy dose level
which is anticipated to require greater than the .4 mCi/kg dose of
90 Y Zevalin recommended for conventional treatment.
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A DECADE OF MYELOABLATIVE HLA-MATCHED SIBLING MARROW
TRANSPLANTATION FOR CHILDREN WITH SEVERE SICKLE CELL DIS-
EASE: OUTCOMES AND LESSONS LEARNED FROM THE ATLANTA EX-
PERIENCE
Haight, A.E.1,2, Rudolph, C.A.1, Eckman, J.R.1,3, Hsu, L.L.3,4, Bow-
man, L.C.1,2, Chiang, K.-Y.2, Olson, E.2, Lauer, M.2, Yeager, A.M.5,
Adamkiewicz, T.1, Olson, T.1,2 1. Emory University School of Medicine,
Atlanta, GA; 2. AFLAC Cancer Center and Blood Disorders Service,
Children’s Healthcare of Atlanta, Atlanta, GA; 3. Georgia Comprehen-
sive Sickle Cell Center, Atlanta, GA; 4. Drexel University/Marian
Anderson Sickle Cell Center, Philadelphia, PA; 5. University of Pitts-
burgh School of Medicine, Pittsburgh, PA
Allogeneic BMT offers a cure to select patients with sickle cell
disease (SCD), but the limited available long-term data and con-
cerns about the risk-to-beneﬁt ratio present dilemmas for families
and clinicians. We report favorable outcomes in a large single
institution experience with myeloablative matched sibling BMT
for children with severe SCD between December 1993 and April
2003. Sixteen patients (12 male) with a median age 7.7 years
(3.3-17.1) were transplanted for primary indications of CVA (n 
8), recurrent TIA (n  1), recurrent ACS (n  6), and frequent
VOC pain (n  1). Graft source was HLA-identical sibling mar-
row, with 9 HgbAS donors. Preparative regimen (BU 14 mg/kg,
CTX 200 mg/kg, ATG 90 mg/kg) was well tolerated. Special
measures included aggressive management of hypertension and
hypomagnesemia, maintenance of Hgb 10-12 g/dl and platelets
50k, and prolonged antiepileptics while on CSA for GVHD
prophylaxis. The initial 8 patients were treated on a multicenter
consortium trial (Walters et al). With median follow-up 36 months
(6-84), OS and DFS are 100% and there are no graft failures. Two
patients have stable mixed chimerism (72 and 69% donor) with low
HgbS (0 and 2.5%) and no clinical SCD. Median WBC engraft-
ment was day 12.5 (10-21) and platelet engraftment day 31.5
(17-46). No patients experienced aGVHD. The two oldest patients
had cGVHD related to medication non-compliance. Two of the 8
patients with prior CVA had serious CNS events, including seizure
and hemorrhage on day 0 in a moya-moya patient and late pro-
gressive cerebrovascular disease in a patient with prior CVA. None
had new clinical CVA. One patient (age 16.7 years) without prior
CVA had a seizure attributed to “non-compliance rebound” with
CSA. Infections included two episodes of Zoster, one early mul-
tiorganism bacteremia, and one late pneumococcal bacteremia. All
patients have excellent functional status and attend school/college.
These favorable outcomes have led our center to offer this trans-
plant treatment as a standard-of-care with principles speciﬁc to
SCD: 1)careful psychosocial screening and transplantation at a
young age, 2)supportive measures to avoid CNS events, and 3)
long-term follow-up with attention to infection and cerebrovascu-
lar disease that may relate to SCD rather than the BMT. In our
experience, collaborative management with a comprehensive sickle
cell program optimizes referral of appropriate patients, reduces
peritransplant complications, and optimizes outcomes.
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BONE MARROW TRANSPLANTATION (BMT) FOR CHILDREN AND AD-
OLESCENTS WITH SEVERE ACQUIRED APLASTIC ANEMIA (SAA): A
SINGLE CENTER EXPERIENCE IN 171 PATIENTS (PTS) COMPARING
TWO DIFFERENT PREPARATORY REGIMENS
Bonﬁm, C.M.S., de Medeiros, C.R., Bitencourt, M.A., Moreira, V.,
Setubal, D.C., Neves, H., Lorenzatto, C., Ruiz, J., Zanis-Neto, J.,
Pasquini, R. Federal University of Parana, Curitiba, PR, Brazil
Background: BMT from a histocompatible sibling is the treat-
ment of choice for young pts with SAA. Those who have received
few transfusions can achieve long term survival after conditioning
with Cyclophosphamide 200mg/kg (CY200). For pts heavily trans-
fused, graft failure (GF) after this regimen is high and led to the
addition of Anti-lymphocyte globulin to improve outcome. Unfor-
tunately this drug is not easily available in developing countries and
from 01/03 on, all pts with more than 15 transfusions pre-BMT
were given Busulfan 12mg/kg (BU12) and CY 120mg/kg (CY120).
Material and Methods: Between 10/79 and 09/03,396 pts with
SAA were transplanted at our BMT Unit. In this study we per-
formed a retrospective analysis in 171 pts 21 years, who received
an HLA-identical sibling transplant (bone marrow), and metho-
trexate  cyclosporine as GVHD immuneprophylaxis. All pts
received prophylactic antibiotics according to common practice.
Preparatory regimen: CY200: 92 pts and BU12/CY120: 79 pts.
Median age at transplant: 13yr (range 1 – 20yr). Gender: 64F/
107M. Median disease duration: 3m (range: 0-232m). Median
transfusions pre-BMT: 23UI (range: 0-238). TNC: 1, 48–12, 9 
108/kg (M: 3, 36). Results: 122 pts are alive and well 263-6141
days post-BMT (M: 2664 days). In the CY200 group 40 pts re-
ceived 15 transfusions and 34 were evaluable for engraftment: 2
pts had primary GF and 20 had late GF (Median: 288 days; range:
100-734 days post-BMT). Mucosytis occurred in 9/92pts.
A-GVHD grade III-IV occurred in 3/84 evaluable pts and exten-
sive C-GVHD in 2/78pts. Estimated overall survival in 16 years is
86% for pts15 transfusions and 50% for pts15 transfusions. In
the BU12/CY120 group, 76 pts were evaluable for engraftment, 1
pt had primary GF and 11 had late GF (median: 524 days post-
BMT). Mucosytis grade III-IV occurred in 27 pts. 8/76pts had
A-GVHD grade III-IV and 8/72pts had extensive C-GVHD. Es-
timated overall survival in this group is 70% (P value  0.002).
Forty-nine pts are dead: Bu12/CY120: 22 pts, CY200  15: 20pts
and CY200  15: 7 pts). .Causes of death in both groups were
mainly related to infection. Conclusion: The BU12  CY120
regimen decreased the GF rate and improved overall survival for
pts heavily transfused but it was associated with more toxicity and
higher transplant related mortality.
SOLID TUMORS
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LESSONS FROM A POSITIVE RANDOMIZED TRIAL OF HIGH-DOSE CHE-
MOTHERAPY IN METASTATIC BREAST CANCER: LEARN FROM OUR
MISTAKES, BUILD ON OUR SUCCESSES, DRAIN THE BATHWATER,
HOLD THE BABY
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Most of the early negative randomized trials of HDC in BC
studied the single-cycle late-intensiﬁcation approach, following
conventional induction therapy. Crown and Norton (Sem Oncol
1995) hypothesized that “induction” CDC might make little cy-
toreductive contribution to a strategy which includes HDC, and
that multiple densely sequenced cycles of HDC might be prefer-
able. In the International Randomized Breast Cancer Dose-Inten-
sity Study (IBDIS-I), patients received a brief phase of CDC
induction, followed by tandem cycles of autograft-supported high-
dose therapy (HDC), or, CDC alone, in chemotherapy-naı¨ve
MBC. Accrual failed in the aftermath of the Bezwoda disclosures,
and only 110 of a planned 264 patients were enrolled. Results:
There were 7 treatment deaths (2-CDC; 5-HDC). Complete and
overall response rates (CR/OR) were signiﬁcantly superior for
HDC v CDC (CR-29% v 6%, OR-71% v 44%). Event-free-
survival at 3 yrs was: HDC 16% versus CDC 9% (p  .0149).
Currently, at a median (med) follow-up of 47 months (range
70-24), 14% of HDC and 7% of CDC pts remain event-free (34%
versus 26% alive, 21% v 11% progression-free). The med duration
of EFS (and OS) were: HDC 428 (961) and CDC 291 (795) days
(EFS: p  0.019, and for survival: p  0.14). Progression–free
survivals were: HDC 439, CDC 322 days (p  .0096). Although
these data appear to conﬂict with the results of other studies, there
were critical design differences between IBDIS and most of the
other trials, which usually applied single high-dose cycles, often
many months after the start of conventional chemotherapy for
metastasis, as “late intensiﬁcation” for patients in ongoing response
to prior CDC. Conclusion: HDC remains a valid investigational
strategy for MBC. The recent report of a second positive “mini-
mum induction/tandem transplant” trial by Nitz et al (ASCO
2003) suggests that the breast oncology and transplant communi-
ties should come together to perform a deﬁnitive investigation of
primary multi-cycle HDC, rather than initiating further studies of
“traditional” single-cycle, late-intensiﬁcation HDC. This approach
will be tested in IBDIS-II.
STEM CELL BIOLOGY
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ALDEHYDE DEHYDROGENASE [ALDH] AND SURFACE ANTIGEN EX-
PRESSION DEFINE HEMATOPOEITIC STEM AND PROGENITOR CELL
[HSPC] SUBSETS DIFFERENTIALLY REPRESENTED IN MOBILIZED PE-
RIPHERAL BLOOD [PBSC], UMBILICAL CORD BLOOD [UCB], AND
BONE MARROW [BM]
Gentry, T., Winstead, L., Deibert, E., Fiordalisi, M., Foster, S.J.,
Pritchard, C., Balber, A.E. STEMCO Biomedical, Inc., Durham, NC
Flow cytometric analysis of ALDH activity identiﬁes HSPC in
UCB, PBSC, and BM as ALDH-bright, side scatter low [ALDHbr-
SSclow] populations. We used a panel of 21 monoclonal antibodies to
compare the immunophenotypes of cells in ALDHbr-SSclow popu-
lations in each type of graft material. BM was obtained from normal
donors; PBSC, from cancer patients or normal donors. UCB samples
were processed with hetastarch or hetastarch and ﬁcoll. Fresh samples
were analyzed after erythrocyte lysis by methods optimized for each
graft type. ALDHbr-SSclow cells comprised 0.5-1.1% of the total
nucleated cells. We collected immunophenotype data from 3000
gated ALDHbr-SSclow cells per sample. In all three graft types,
90% of the ALDHbr-SSclow cells expressed no lineage marker
characteristic of mature lymphocytes, NK cells, monocytes, or devel-
oping erythrocytes. However, the ALDHbr-SSclow population in
each graft type was composed of different proportions of cells express-
ing surface markers associated with HSPC function. First, the pro-
portion of primitive CD34CD38-cells in the ALDHbr-SSclow
population was considerably higher, and expression of the myeloid
lineage markers CD13 and CD33 was lower, in UCB than in PBSC
or BM. Second, the ALDHbr-SSclow population in UCB, but not in
PBSC or BM populations, included about four times more CD7
cells than CD3 cells, suggesting that CD7 lymphoid progenitors
are enriched in the UCB population. Third, BM ALDHbr-SSclow
cells were enriched about 50-fold for CD105, a marker associated
with hematopoeitic and non-hematpoietic stem cell functions, and
about 2-fold for both stem cell growth factor receptor CD117 and the
early differentiation marker CD41 relative to populations from PBSC
and UCB. Finally, cells expressing CD133 were about 2.5 times more
frequent in PBSC than in BM or UCB. The proportion of the total
population of cells expressing a given surface marker that also had the
ALDHbr-SSclow phenotype varied from 88.5% of the CD34 cells
in PBSC to 1.2% of CD90 cells in UCB. In some cases, the
proportion of cells expressing a given marker that also ALDHbr-
SSclow was different in different graft types. For example, 64.1% of
the CD105 cells in BM, but 0.5% of the CD105 cells in UCB and
PBSC, were ALDHbr-SSclow. Thus, ALDH expression and surface
antigen expression together deﬁne new stem/progenitor cell subsets
that are differentially represented in the three types of hematopoeitic
graft material we analyzed.
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PREVENTION OF CYTOMEGALOVIRUS (CMV) REACTIVATION BY STAN-
DARD DOSE VALACYCLOVIR (VACV) AFTER ALLOGENEIC BONE MAR-
ROW TRANSPLANTATION
Mori, T., Shimizu, T., Aisa, Y., Ikeda, Y., Okamoto, S. Division of
Hematology, Keio Univ. School of Medicine, Tokyo, Japan
In spite of the advances in the strategies against CMV reactiva-
tion and subsequent disease, including preemptive or prophylactic
administration of ganciclovir, CMV disease causes signiﬁcant mor-
bidity and mortality in high-risk patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT). Although ganci-
clovir is highly effective against CMV, its myelotoxicity is associ-
ated with secondary infection and reduced survival. In contrast,
acyclovir and its prodrug VACV have a more favorable safety
proﬁle. A recent study showed a signiﬁcant reduction in the inci-
dence of CMV reactivation after allogeneic HSCT with high-dose
VACV (8000 mg/day) as compared with acyclovir (Ljungman P, et
al, 2002). We have examined an efﬁcacy of standard dose VACV in
the prevention of CMV reactivation after allogeneic bone marrow
transplantation (BMT). Twelve CMV seropositive recipients
and/or donor subjects, who underwent allogeneic BMT from an
HLA-matched unrelated donor, were enrolled. Patients were con-
ditioned with TBI- or busulfan-based myeloablative conditioning
regimens. Patients received i.v. acyclovir (750 mg/dody/day) from
day-3 until patients became capable of taking oral VACV. VACV
was initiated at a dose of 3000 mg/day and continued until day 100.
CMV reactivation was monitored by CMV antigenemia assay and
real-time PCR using plasma. Thirty-ﬁve patients undergoing un-
related BMT without any prophylactic therapy against CMV were
used as a comparable control. CMV reactivation was detected in 4
of 12 patients (33%) as compared with 24 of 35 (68.6%) in a
control (P0.05). Among the 4 patients with CMV reactivation, 2
preemptively received ganciclovir, while CMV reactivation became
undetectable with VACV alone in the 2 remaining patients. No
case developed CMV disease, while 14% developed CMV disease
in a control (not signiﬁcant). Adverse events probably due to
VACV include nausea in 2 patients, and thromobocytopenia in 2
patients. These data strongly suggested that standard dose VACV
could safely and effectively prevent CMV reactivation in high-risk
patients undergoing allogeneic HSCT.
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